Phase 3
N=541
A Safety Study of 3 Different Bowel Cleansing Preparations
Colonoscopy · Bowel Preparation · Endoscopy
Bottom Line
View on ClinicalTrials.gov: NCT01501513 ↗Enrolled (actual)
541
Serious AEs
3.5%
Results posted
Jan 2024
Primary outcome: Primary: Percentage of Subjects With Successful Bowel Preparation — 175; 132; 137 Participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- PEG-3350 based bowel preparation (Drug); BLI800 approved preparation regimen (Drug); BLI800 investigational preparation regimen (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Braintree Laboratories
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Subjects With Successful Bowel Preparation |
175; 132; 137 | <0.001 sig |
| SECONDARY Count and Percentage of Subjects With Adverse Events Through Day of Colonoscopy |
79; 75; 83; 65; 56; 50 | — |
| SECONDARY Count and Percentage of Subjects With Adverse Events After Colonoscopy Through Follow-up Day 7 |
3; 11; 7; 10; 18; 25 | — |
Summary
The objective of this study is to compare the safety, tolerance and efficacy of BLI800 (approved and investigational regimens) to an approved control preparation as bowel preparations prior to colonoscopy in adult patients, particularly including the elderly and those with renal and/or hepatic impairment.
Eligibility Criteria
Inclusion Criteria
- Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
- At least 18 years of age
- If female, and of child-bearing potential, is using an acceptable form of birth control
- Negative urine pregnancy test at screening, if applicable
- In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
Exclusion Criteria
- Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
- Subjects who had previous significant gastrointestinal surgeries.
- Subjects who have uncontrolled clinically significant pre-existing electrolyte disturbances.
- Subjects with severe liver or renal insufficiency.
- Subjects with a history of congestive heart failure or other clinically significant cardiac abnormality.
- Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- Subjects undergoing colonoscopy for foreign body removal and decompression.
- Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- Subjects of childbearing potential who refuse a pregnancy test.
- Subjects allergic to any preparation components
- Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.
Data sourced from ClinicalTrials.gov (NCT01501513). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.